Industry News

Novartis announced that it will present 33 scientific abstracts at the Annual European Congress of Rheumatology (EULAR 2016) in London, UK. This includes new long-term analyses suggesting Cosentyx® (secukinumab) may lead to higher responses than Humira (adalimumab) in improving the signs and symptoms of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) at 52 weeks.  These analyses are from two studies using the Matching-Adjusted Indirect Comparisons (MAIC) method. MAIC is a valid and accepted method for comparative effectiveness research.

Roche announced that the European Commission has approved the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)-activating mutations.

Allergan plc announced the approval of BYVALSON™ (nebivolol and valsartan) 5 mg/ 80 mg tablets, by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension to lower blood pressure. BYVALSON is the first and only fixed-dose combination (FDC) of a beta blocker (BB) and angiotensin II receptor blocker (ARB) available in the U.S.

Amgen announced the launch of Kyprolis Central, an online media resource about the impact of living with relapsed or refractory multiple myeloma. Intended to drive awareness of a rare blood cancer that is increasingly becoming more prevalent in the United States (US), Kyprolis Central provides real-life stories from relapsed multiple myeloma patients, as well as educational materials and third party resources.

[adsense:336x280:8701650588]

Adamis Pharmaceuticals Corporation announced that after the close of the stock markets on June 3, 2016 it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe (PFS) product.  PFS is for the emergency treatment of acute anaphylaxis, which is a severe allergic reaction.   A CRL is issued by the FDA's Center for Drug Evaluation and Research when it has

Eli Lilly and Company announced that clinical study data from two of its ongoing immuno-oncology clinical collaborations with Merck were presented this weekend at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO). Specifically, data were presented from two early-phase trials evaluating ALIMTA® (pemetrexed)-plus-carboplatin and CYRAMZA® (ramucirumab), respectively, in combination with Merck's KEYTRUDA® (pembrolizumab), in patients with non-small cell lung cancer (NSCLC).

Mylan N.V. announced the U.S. launch of Clindamycin Palmitate Hydrochloride for Oral Solution USP, 75 mg/5 mL, which is a generic version of Pharmacia and Upjohn's Cleocin® Solution. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneumococci and staphylococci when less toxic alternatives are inappropriate.

Mylan N.V. and Biocon Ltd. announced the presentation of data from the HERITAGE study at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7. The study confirmed the efficacy, safety and immunogenicity of MYL-1401O, the proposed biosimilar trastuzumab co-developed by Biocon and Mylan, in comparison to branded trastuzumab.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that a one-year phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.